{
  "run_id": "RUN_20260204_132700_1fed028ce5fb",
  "timestamp": "2026-02-04T15:31:32.857110",
  "document": "03_Protocol_ALXN1720-oMG-303.pdf",
  "document_path": "/Users/frederictetard/Projects/ese/gold_data/PAPERS/03_Protocol_ALXN1720-oMG-303.pdf",
  "pipeline_version": "0.8",
  "total_candidates": 54,
  "total_validated": 54,
  "total_rejected": 0,
  "total_ambiguous": 0,
  "diseases": [
    {
      "matched_text": "xX",
      "preferred_label": "46,XX testicular difference of sex development",
      "abbreviation": "XX",
      "confidence": 0.95,
      "is_rare_disease": true,
      "category": "rare_disease",
      "codes": {
        "icd10": "Q99.1",
        "icd11": "LD2A.Y",
        "snomed": null,
        "mondo": null,
        "orpha": "ORPHA:393",
        "umls": null,
        "mesh": null
      },
      "all_identifiers": [
        {
          "system": "ORPHA",
          "code": "ORPHA:393",
          "display": null
        },
        {
          "system": "ICD-10",
          "code": "Q99.1",
          "display": null
        },
        {
          "system": "ICD-11",
          "code": "LD2A.Y",
          "display": null
        }
      ],
      "context": "cal Deterioratio n Study Day D1 D8 D15 | D22 | D29 | D36 | D43 | D50 D57 D64 D71 D78 D85 Window (day[s]) +1 +1 +1 +1] +1 +1 +1 +1 +1 +1 +1 +1 Weeks we wi W2 W3 W4 | W5 W6 W7 ws w9 wi0 Wil Wwi2 Visit Type Cc Cc Cc Cc R Cc R Cc R Cc R R R Cc Cc Cc C = Clinic Visit R = Remote Visit Efficacy MGII (PRO) xX xX xX xX xX xX xX xX xX xX xX MGII (Exam) xX xX xX xX xX xX xX xX MG-ADL xX xX xX xX xX xX xX xX xX xX x xX x xX xX xX NEI-VFQ-25 xX xX xX xX xX xX xX xX MG-QoL15r xX xX xX xX xX xX xX Neuro-QoL fatigue XxX Xx XxX XxX XxX XxX (short form) SF-36° xX xX xX xX xX xX PGI-S (ocular) xX xX xX xX xX xX xX",
      "page": 22,
      "mention_count": 1,
      "pages_mentioned": [
        22
      ],
      "lexicon_source": "2025_08_rare_disease_acronyms.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "SIP",
      "preferred_label": "Spontaneous intestinal perforation",
      "abbreviation": "SIP",
      "confidence": 0.95,
      "is_rare_disease": true,
      "category": "gastroenterology",
      "codes": {
        "icd10": "K63.1",
        "icd11": "KB84",
        "snomed": null,
        "mondo": null,
        "orpha": "ORPHA:645793",
        "umls": null,
        "mesh": "D018813"
      },
      "all_identifiers": [
        {
          "system": "ORPHA",
          "code": "ORPHA:645793",
          "display": null
        },
        {
          "system": "ICD-10",
          "code": "K63.1",
          "display": null
        },
        {
          "system": "ICD-11",
          "code": "KB84",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D018813",
          "display": "Multiple Endocrine Neoplasia Type 2a"
        }
      ],
      "context": "analysis will be conducted such that the ongoing study integrity is maintained. An ISC will conduct the interim analysis and investigators, participants, and the study team who are involved in the conduct of the study will remain masked to treatment assignment until the final clinical data lock. A SIP will be developed in which the masking method and unmasking process will be pre-specified.",
      "page": 19,
      "mention_count": 1,
      "pages_mentioned": [
        19
      ],
      "lexicon_source": "2025_08_rare_disease_acronyms.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Multiple Endocrine Neoplasia Type 2a",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "ALT",
      "preferred_label": "Well-differentiated liposarcoma",
      "abbreviation": "ALT",
      "confidence": 0.6,
      "is_rare_disease": true,
      "category": "oncology",
      "codes": {
        "icd10": "C49.9",
        "icd11": null,
        "snomed": null,
        "mondo": null,
        "orpha": "ORPHA:99971",
        "umls": null,
        "mesh": "D008080"
      },
      "all_identifiers": [
        {
          "system": "ORPHA",
          "code": "ORPHA:99971",
          "display": null
        },
        {
          "system": "ICD-10",
          "code": "C49.9",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D008080",
          "display": "Liposarcoma"
        }
      ],
      "context": "— ALT>2 x the ULN",
      "page": 12,
      "mention_count": 1,
      "pages_mentioned": [
        12
      ],
      "lexicon_source": "2025_08_rare_disease_acronyms.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Liposarcoma",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "IPD",
      "preferred_label": "Infantile dystonia-parkinsonism",
      "abbreviation": "IPD",
      "confidence": 0.95,
      "is_rare_disease": true,
      "category": "neurology",
      "codes": {
        "icd10": "G24.8",
        "icd11": "8A02.12",
        "snomed": null,
        "mondo": null,
        "orpha": "ORPHA:238455",
        "umls": null,
        "mesh": null
      },
      "all_identifiers": [
        {
          "system": "ORPHA",
          "code": "ORPHA:238455",
          "display": null
        },
        {
          "system": "ICD-10",
          "code": "G24.8",
          "display": null
        },
        {
          "system": "ICD-11",
          "code": "8A02.12",
          "display": null
        }
      ],
      "context": "ther complement inhibitors, FeRni’s, B-cell-depleting therapies): OMG SOC; B cell depleting therapies in past or present collected and that “If more than 3 items are missing for the same assessment, the assessment may be invalid” tSDV; Document incomplete collection as Important Protocol Deviation (IPD). Discussion: Highlighted past issues in the GA trial where incomplete data collection led to invalid results, stressing the need for accuracy, especially at baseline, due to the short, randomized control period. Additional strategies like site coordinator calls during visits are suggested for ensu",
      "page": 46,
      "mention_count": 1,
      "pages_mentioned": [
        46
      ],
      "lexicon_source": "2025_08_rare_disease_acronyms.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "inflammatory bowel disease",
      "preferred_label": "inflammatory bowel disease",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "gastroenterology",
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0005265",
        "orpha": null,
        "umls": "UMLS:C0021390",
        "mesh": "MESH:D015212"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0005265",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:0050589",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0003767",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:558.9",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:43877",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D015212",
          "display": null
        },
        {
          "system": "NANDO",
          "code": "NANDO:2100259",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C3138",
          "display": null
        },
        {
          "system": "OMIMPS",
          "code": "OMIMPS:266600",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:24526004",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0021390",
          "display": null
        }
      ],
      "context": "ponsible for the disease’s pathophysiology. Achievement and maintenance of a status at which clinical signs and symptoms of the underlying condition are absent or minimally present is widely accepted as the treatment goal for various chronic disabling immuno-mediated diseases (eg, bronchial asthma, inflammatory bowel disease, multiple sclerosis, and rheumatoid arthritis).",
      "page": 2,
      "mention_count": 1,
      "pages_mentioned": [
        2
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Colitis Ulcerative",
        "Crohn Disease",
        "Inflammatory Bowel Disease 2"
      ],
      "pubtator_normalized_name": "Inflammatory Bowel Diseases",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "SDs",
      "preferred_label": "Shwachman-Diamond syndrome",
      "abbreviation": "SDS",
      "confidence": 0.95,
      "is_rare_disease": true,
      "category": "rare_disease",
      "codes": {
        "icd10": "D61.0",
        "icd11": "3A70.0",
        "snomed": null,
        "mondo": null,
        "orpha": "ORPHA:811",
        "umls": null,
        "mesh": "D000081003"
      },
      "all_identifiers": [
        {
          "system": "ORPHA",
          "code": "ORPHA:811",
          "display": null
        },
        {
          "system": "ICD-10",
          "code": "D61.0",
          "display": null
        },
        {
          "system": "ICD-11",
          "code": "3A70.0",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D000081003",
          "display": "Shwachman-Diamond Syndrome"
        }
      ],
      "context": "PFS-SDs containing gefurulimab or placebo will be provided in identical study intervention kits and with identical labels for all participants in the RCT Period. Yellow transparent tape will cover the PFS-SDs to conceal the color difference between gefurulimab and placebo. Because the viscosity of gefuruli",
      "page": 15,
      "mention_count": 1,
      "pages_mentioned": [
        15
      ],
      "lexicon_source": "2025_08_rare_disease_acronyms.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Shwachman-Diamond Syndrome",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "fungal infection",
      "preferred_label": "fungal infectious disease",
      "abbreviation": null,
      "confidence": 0.85,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": "ICD10CM:B35-B49",
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0002041",
        "orpha": null,
        "umls": "UMLS:C0026946",
        "mesh": "MESH:D009181"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0002041",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:1564",
          "display": null
        },
        {
          "system": "ICD-10-CM",
          "code": "ICD10CM:B35-B49",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:117.9",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:6486",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D009181",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C3245",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:3218000",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0026946",
          "display": null
        }
      ],
      "context": "Active systemic bacterial, viral, or fungal infection < 14 days prior to Day 1.",
      "page": 11,
      "mention_count": 1,
      "pages_mentioned": [
        11
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "HCP",
      "preferred_label": "hereditary coproporphyria",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0007369",
        "orpha": "Orphanet:79273",
        "umls": "UMLS:C0162531",
        "mesh": "MESH:D046349"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0007369",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:13269",
          "display": null
        },
        {
          "system": "GARD",
          "code": "GARD:6619",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:57931",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D046349",
          "display": null
        },
        {
          "system": "MedDRA",
          "code": "MedDRA:10019866",
          "display": null
        },
        {
          "system": "NANDO",
          "code": "NANDO:2201264",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C84759",
          "display": null
        },
        {
          "system": "NORD",
          "code": "NORD:1228",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "OMIM:121300",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:79273",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:7425008",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0162531",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:1365918274",
          "display": null
        }
      ],
      "context": "PROs like MGI and MG-ADL in Prevail were administered by site staff over the phone, not independently by patients at home, ensuring control. RISK 2: Viscosity differences pose a_ | Risk 2: Mitigate risk during the RCT to OLE transition | The dose at the transition from RCT to OLE is administered by HCP (Week 12) Discussion: Patients remained blinded during RCT. Viscosity differences pose a risk during the RCT to OLE transition where patients may receive mixed active and placebo syringes. It was explained that Healthcare Professionals (HCPs) administer these doses to prevent patients from feeling",
      "page": 49,
      "mention_count": 1,
      "pages_mentioned": [
        49
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "OMG",
      "preferred_label": "Ocular myasthenia gravis",
      "abbreviation": "OMG",
      "confidence": 0.95,
      "is_rare_disease": true,
      "category": "ophthalmology",
      "codes": {
        "icd10": "G70.0",
        "icd11": "8C60",
        "snomed": null,
        "mondo": null,
        "orpha": "ORPHA:589",
        "umls": null,
        "mesh": "D009157"
      },
      "all_identifiers": [
        {
          "system": "ORPHA",
          "code": "ORPHA:589",
          "display": null
        },
        {
          "system": "ICD-10",
          "code": "G70.0",
          "display": null
        },
        {
          "system": "ICD-11",
          "code": "8C60",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D009157",
          "display": "Myasthenia Gravis"
        }
      ],
      "context": "A study to investigate safety and efficacy of gefurulimab compared with placebo in participants aged > 18 years of age with OMG",
      "page": 1,
      "mention_count": 2,
      "pages_mentioned": [
        1,
        2
      ],
      "lexicon_source": "2025_08_rare_disease_acronyms.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Myasthenia Gravis",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "viral infection",
      "preferred_label": "viral infectious disease",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0005108",
        "orpha": null,
        "umls": null,
        "mesh": "MESH:D014777"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0005108",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:934",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0000763",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:079.99",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D014777",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C3439",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:34014006",
          "display": null
        }
      ],
      "context": "e Evidence of hepatitis B or hepatitis C viral infection or presence of HBsAg or HBcAb with negative surface antibody (anti-HBs), or HCV infection (HCV antibody positive, expect for participants with document successful treatment). If locally available, SVR should be documented or established at Screening.",
      "page": 13,
      "mention_count": 1,
      "pages_mentioned": [
        13
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "meningococcal infection",
      "preferred_label": "meningococcal infection",
      "abbreviation": null,
      "confidence": 0.85,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": "ICD10CM:A39",
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0005373",
        "orpha": null,
        "umls": "UMLS:C0025303",
        "mesh": "MESH:D008589"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0005373",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0004249",
          "display": null
        },
        {
          "system": "ICD-10-CM",
          "code": "ICD10CM:A39",
          "display": null
        },
        {
          "system": "ICD10WHO",
          "code": "ICD10WHO:A39",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:036.9",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:7537",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D008589",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:23511006",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0025303",
          "display": null
        }
      ],
      "context": "To reduce the risk of meningococcal infection, all participants must be vaccinated against NV meningitidis serogroups A, C, W135, Y, (and where available, serogroup B) within 3 years prior to Day 1. Participants who do not meet this requirement will be vaccinated against these N meningitidis serogroups before receiving the first dose of the st",
      "page": 11,
      "mention_count": 1,
      "pages_mentioned": [
        11
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Meningococcal Infections",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "Eye",
      "preferred_label": "Kapur-Toriello syndrome",
      "abbreviation": null,
      "confidence": 0.6,
      "is_rare_disease": true,
      "category": "rare_disease",
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": null,
        "orpha": "ORPHA:2328",
        "umls": null,
        "mesh": null
      },
      "all_identifiers": [
        {
          "system": "ORPHA",
          "code": "ORPHA:2328",
          "display": null
        }
      ],
      "context": "NEI-VFQ-25 National Eye Institute Visual Functioning Questionnaire-25",
      "page": 35,
      "mention_count": 1,
      "pages_mentioned": [
        35
      ],
      "lexicon_source": "2025_08_orphanet_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "MAC",
      "preferred_label": "Middle aortic syndrome",
      "abbreviation": "MAC",
      "confidence": 0.95,
      "is_rare_disease": true,
      "category": "cardiology",
      "codes": {
        "icd10": "Q25.1",
        "icd11": "LA8B.21",
        "snomed": null,
        "mondo": null,
        "orpha": "ORPHA:1456",
        "umls": null,
        "mesh": "D008268"
      },
      "all_identifiers": [
        {
          "system": "ORPHA",
          "code": "ORPHA:1456",
          "display": null
        },
        {
          "system": "ICD-10",
          "code": "Q25.1",
          "display": null
        },
        {
          "system": "ICD-11",
          "code": "LA8B.21",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D008268",
          "display": "Macular Degeneration"
        }
      ],
      "context": "Evidence of complement activity in anti-AChR antibody-positive gMG is provided by histopathological findings of complement deposition and MAC formation at motor end plates, studies demonstrating interference of AChR autoantibodies with functional domains of the AChR (Li, 2025) and NMJ destruction in the presence of MACs (Engel, 1977), experimental models of autoimmune myasthenia gravis (EAMG) (Tiiziin, 2013), and the established clinical",
      "page": 2,
      "mention_count": 1,
      "pages_mentioned": [
        2
      ],
      "lexicon_source": "2025_08_rare_disease_acronyms.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Vision Disorders",
        "Macular Edema",
        "Macrophage Activation Syndrome"
      ],
      "pubtator_normalized_name": "Macular Degeneration",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "pH",
      "preferred_label": "Pulmonary hypertension",
      "abbreviation": "PH",
      "confidence": 1.0,
      "is_rare_disease": false,
      "category": "pulmonology",
      "codes": {
        "icd10": "I27.0",
        "icd11": "BB01",
        "snomed": "70995007",
        "mondo": null,
        "orpha": "ORPHA:182090",
        "umls": "C0020542",
        "mesh": "D006976"
      },
      "all_identifiers": [
        {
          "system": "ORPHA",
          "code": "ORPHA:182090",
          "display": null
        },
        {
          "system": "ICD-10",
          "code": "I27.0",
          "display": null
        },
        {
          "system": "ICD-10-CM",
          "code": "I27.20",
          "display": null
        },
        {
          "system": "ICD-11",
          "code": "BB01",
          "display": null
        },
        {
          "system": "SNOMED-CT",
          "code": "70995007",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "C0020542",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D006976",
          "display": null
        }
      ],
      "context": "Group Name Treatment 1 Treatment 2 Intervention Name ALXN1720-PFS-SD Placebo-PFS-SD Type Integral medicinal product: biological product and device Integral medicinal product: placebo formulation and device Dose Formulation Sterile liquid gefurulimab is formulated at pH 6.7 and each syringe contains 300 mg of gefurulimab in 20 mM L-histidine/histidine hydrochloride, 100 mM glycine, 200 mM sucrose, 0.08% (w/v) polysorbate 80 Device configuration/style/model: BD 2.25mL Neopak™ Prefilled Syringe with Ultrasafe Plus™ Passive Needle Safety Device Sterile liquid gefurul",
      "page": 14,
      "mention_count": 1,
      "pages_mentioned": [
        14
      ],
      "lexicon_source": "disease_lexicon_pah.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Pulmonary Arterial Hypertension",
        "Familial Primary Pulmonary Hypertension",
        "Pulmonary edema of mountaineers"
      ],
      "pubtator_normalized_name": "Hypertension Pulmonary",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "FAS",
      "preferred_label": "Fetal alcohol syndrome",
      "abbreviation": "FAS",
      "confidence": 0.6,
      "is_rare_disease": true,
      "category": "rare_disease",
      "codes": {
        "icd10": "Q86.0",
        "icd11": "LD2F.00",
        "snomed": null,
        "mondo": null,
        "orpha": "ORPHA:1915",
        "umls": null,
        "mesh": "D063647"
      },
      "all_identifiers": [
        {
          "system": "ORPHA",
          "code": "ORPHA:1915",
          "display": null
        },
        {
          "system": "ICD-10",
          "code": "Q86.0",
          "display": null
        },
        {
          "system": "ICD-11",
          "code": "LD2F.00",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D063647",
          "display": "Fetal Alcohol Spectrum Disorders"
        }
      ],
      "context": "The Full Analysis Set (FAS) will be the primary population used for the analysis of all efficacy endpoints for the RCT Period. Supplemental per protocol analyses for primary and secondary efficacy endpoints will be performed based on the Per Protocol Set (PPS) in the same manner as done for the FAS. Safety analyses will be p",
      "page": 16,
      "mention_count": 1,
      "pages_mentioned": [
        16
      ],
      "lexicon_source": "2025_08_rare_disease_acronyms.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Fetal Alcohol Spectrum Disorders",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "EH",
      "preferred_label": "Epithelioid hemangioma",
      "abbreviation": "EH",
      "confidence": 0.6,
      "is_rare_disease": true,
      "category": "rare_disease",
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": null,
        "orpha": "ORPHA:675396",
        "umls": null,
        "mesh": null
      },
      "all_identifiers": [
        {
          "system": "ORPHA",
          "code": "ORPHA:675396",
          "display": null
        }
      ],
      "context": "Engel AG, Lambert EH, Howard FM. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc. 1977;52(5):267-280.",
      "page": 38,
      "mention_count": 1,
      "pages_mentioned": [
        38
      ],
      "lexicon_source": "2025_08_rare_disease_acronyms.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "CAPA",
      "preferred_label": "episodic ataxia type 2",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0007163",
        "orpha": "Orphanet:97",
        "umls": "UMLS:C1720416",
        "mesh": "MESH:C535506"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0007163",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:0050990",
          "display": null
        },
        {
          "system": "GARD",
          "code": "GARD:9602",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:314039",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:C535506",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "OMIM:108500",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:97",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:420932006",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C1720416",
          "display": null
        }
      ],
      "context": "te initiation visits and ongoing staff training. Pre-study verification of access to refrigerated centrifuge at all sample collection sites. Monitoring of sample processing conditions (time, temperature, device ID) on laboratory log. Reporting protocol deviations with prompt root-cause analysis and CAPA. Risk 8: Mitigate Require real-time documentation of dosing details (amount, date, time, injection site). Train sites on accurate recording; implement eCRF fields for dosing data. Engage patient logs and source verification to ensure completeness. Train subjects since they will self-administer and",
      "page": 47,
      "mention_count": 1,
      "pages_mentioned": [
        47
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "neuromuscular disease",
      "preferred_label": "neuromuscular disease",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "neurology",
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0019056",
        "orpha": "Orphanet:68381",
        "umls": "UMLS:C0027868",
        "mesh": "MESH:D009468"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0019056",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:440",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:1001902",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:358.9",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:10323",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D009468",
          "display": null
        },
        {
          "system": "MedDRA",
          "code": "MedDRA:10029323",
          "display": null
        },
        {
          "system": "NANDO",
          "code": "NANDO:2100214",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:68381",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0027868",
          "display": null
        }
      ],
      "context": "Blocking terminal complement activity is now an established effective therapeutic approach to gMG that has been endorsed by neuromuscular disease experts in treatment guidelines (Narayanaswami, 2021; Sanders, 2016).",
      "page": 2,
      "mention_count": 1,
      "pages_mentioned": [
        2
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Neuromuscular Manifestations",
        "Neuromuscular Diseases",
        "Neuromuscular Disease Congenital With Uniform Type 1 Fiber"
      ],
      "pubtator_normalized_name": "Neuromuscular Junction Diseases",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "rheumatoid arthritis",
      "preferred_label": "rheumatoid arthritis",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "immunology",
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0008383",
        "orpha": "Orphanet:284130",
        "umls": "UMLS:C0003873",
        "mesh": "MESH:D001172"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0008383",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:7148",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0000685",
          "display": null
        },
        {
          "system": "HP",
          "code": "HP:0001370",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:714.0",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:2078",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D001172",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C2884",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "OMIM:180300",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:284130",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:69896004",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0003873",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:576319925",
          "display": null
        }
      ],
      "context": "ent and maintenance of a status at which clinical signs and symptoms of the underlying condition are absent or minimally present is widely accepted as the treatment goal for various chronic disabling immuno-mediated diseases (eg, bronchial asthma, inflammatory bowel disease, multiple sclerosis, and rheumatoid arthritis).",
      "page": 2,
      "mention_count": 1,
      "pages_mentioned": [
        2
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Arthritis Juvenile",
        "Rheumatoid Arthritis Systemic Juvenile",
        "Felty Syndrome"
      ],
      "pubtator_normalized_name": "Arthritis Rheumatoid",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "multiple sclerosis",
      "preferred_label": "multiple sclerosis",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "neurology",
      "codes": {
        "icd10": "ICD10CM:G35",
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0005301",
        "orpha": "Orphanet:802",
        "umls": "UMLS:C0026769",
        "mesh": "MESH:D009103"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0005301",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:2377",
          "display": null
        },
        {
          "system": "ICD-10-CM",
          "code": "ICD10CM:G35",
          "display": null
        },
        {
          "system": "ICD10WHO",
          "code": "ICD10WHO:G35",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:340",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:10123",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D009103",
          "display": null
        },
        {
          "system": "NANDO",
          "code": "NANDO:2200904",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C3243",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:802",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:24700007",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0026769",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:1298865187",
          "display": null
        }
      ],
      "context": "athophysiology. Achievement and maintenance of a status at which clinical signs and symptoms of the underlying condition are absent or minimally present is widely accepted as the treatment goal for various chronic disabling immuno-mediated diseases (eg, bronchial asthma, inflammatory bowel disease, multiple sclerosis, and rheumatoid arthritis).",
      "page": 2,
      "mention_count": 1,
      "pages_mentioned": [
        2
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Multiple Sclerosis Relapsing-Remitting",
        "Multiple Sclerosis Chronic Progressive",
        "Ribbing disease"
      ],
      "pubtator_normalized_name": "Multiple Sclerosis",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "autoimmune disease",
      "preferred_label": "autoimmune disease",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "immunology",
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0007179",
        "orpha": null,
        "umls": "UMLS:C0004364",
        "mesh": "MESH:D001327"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0007179",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:417",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0005809",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:720",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:2135",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D001327",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C2889",
          "display": null
        },
        {
          "system": "OBI",
          "code": "OBI:1110054",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "OMIM:109100",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:85828009",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0004364",
          "display": null
        }
      ],
      "context": "e Known other autoimmune disease that may affect study participation and results in the opinion of PI and medical monitor",
      "page": 11,
      "mention_count": 1,
      "pages_mentioned": [
        11
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Autoimmune Diseases of the Nervous System",
        "Demyelinating Autoimmune Diseases CNS",
        "Purpura Thrombocytopenic Idiopathic"
      ],
      "pubtator_normalized_name": "Autoimmune Diseases",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "Myasthenia Gravis",
      "preferred_label": "myasthenia gravis",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": "ICD10CM:G70.0",
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0009688",
        "orpha": "Orphanet:589",
        "umls": "UMLS:C0026896",
        "mesh": "MESH:D009157"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0009688",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:437",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0004991",
          "display": null
        },
        {
          "system": "GARD",
          "code": "GARD:7122",
          "display": null
        },
        {
          "system": "ICD-10-CM",
          "code": "ICD10CM:G70.0",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:358.00",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:7764",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D009157",
          "display": null
        },
        {
          "system": "MedDRA",
          "code": "MedDRA:10028417",
          "display": null
        },
        {
          "system": "NANDO",
          "code": "NANDO:2200906",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C60989",
          "display": null
        },
        {
          "system": "NORD",
          "code": "NORD:1478",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "OMIM:254200",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:589",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:91637004",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0026896",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:1270100227",
          "display": null
        }
      ],
      "context": "A Phase 3, Randomized, Double-masked, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Gefurulimab in Participants > 18 years of age with Ocular Myasthenia Gravis",
      "page": 1,
      "mention_count": 2,
      "pages_mentioned": [
        1,
        2
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Myasthenia Gravis Autoimmune Experimental",
        "Myasthenic Syndromes Congenital",
        "Myasthenia Gravis Neonatal"
      ],
      "pubtator_normalized_name": "Myasthenia Gravis",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "hypersensitivity",
      "preferred_label": "hypersensitivity",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0000605",
        "orpha": null,
        "umls": "UMLS:C3532523",
        "mesh": "D006969"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0000605",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:0060056",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:1002003",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:759636",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C3114",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:473010000",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C3532523",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D006969",
          "display": "Hypersensitivity Immediate"
        }
      ],
      "context": "e History of hypersensitivity to any ingredient contained in the study intervention, including its device components",
      "page": 11,
      "mention_count": 3,
      "pages_mentioned": [
        11,
        30,
        42
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Drug Hypersensitivity",
        "Hypersensitivity Delayed",
        "Hypersensitivity"
      ],
      "pubtator_normalized_name": "Hypersensitivity Immediate",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "immunodeficiency",
      "preferred_label": "immunodeficiency",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "immunology",
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0021094",
        "orpha": null,
        "umls": "UMLS:C0021051",
        "mesh": "D000163"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0021094",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:279.3",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:7034",
          "display": null
        },
        {
          "system": "NANDO",
          "code": "NANDO:2100204",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C3131",
          "display": null
        },
        {
          "system": "OMIMPS",
          "code": "OMIMPS:300755",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:234532001",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0021051",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D000163",
          "display": "Acquired Immunodeficiency Syndrome"
        }
      ],
      "context": "Abbreviation or | Explanation Term HBsAg hepatitis B surface antigen HCV hepatitis C virus Hib Haemophilus influenzae type b HIV human immunodeficiency virus HRT hormone replacement therapy IAS immunogenicity analysis set IE intercurrent event IEC Independent Ethics Committee IgG immunoglobulin G IMP investigational medicinal product IRB Institutional Review Board IRT interactive response technology ISC independent statistical center IVIg intraven",
      "page": 35,
      "mention_count": 1,
      "pages_mentioned": [
        35
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Immunodeficiency due to Defect in MAPBP-Interacting Protein",
        "Lymphoproliferative Disorders",
        "X-Linked Combined Immunodeficiency Diseases"
      ],
      "pubtator_normalized_name": "Acquired Immunodeficiency Syndrome",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "MD",
      "preferred_label": "Menkes disease",
      "abbreviation": "MD",
      "confidence": 0.6,
      "is_rare_disease": true,
      "category": "rare_disease",
      "codes": {
        "icd10": "E83.0",
        "icd11": "5C64.0Y",
        "snomed": null,
        "mondo": null,
        "orpha": "ORPHA:565",
        "umls": null,
        "mesh": "D007706"
      },
      "all_identifiers": [
        {
          "system": "ORPHA",
          "code": "ORPHA:565",
          "display": null
        },
        {
          "system": "ICD-10",
          "code": "E83.0",
          "display": null
        },
        {
          "system": "ICD-11",
          "code": "5C64.0Y",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D007706",
          "display": "Menkes Kinky Hair Syndrome"
        }
      ],
      "context": "08% (w/v) polysorbate 80 Device configuration/style/model: BD 2.25mL Neopak™ Prefilled Syringe with Ultrasafe Plus™ Passive Needle Safety Device Unit Dose Strength | 300 mg (2 mL = 150 mg/mL) placebo (2 mL) Dosage Level 600 mg LD (on Day 1) + 300 mg Same number of injections as (TBD and Subject Q1W MD (starting Day 8) gefurulimab to change) during the RCT Period. during the RCT Period. For dosing during the OLE Period, | For dosing during the OLE Period, see see Section 4.3 Section 4.3 Route of SC injection SC injection Administration Use Experimental Placebo IMP or AxMP IMP IMP Sourcing Provide",
      "page": 14,
      "mention_count": 1,
      "pages_mentioned": [
        14
      ],
      "lexicon_source": "2025_08_rare_disease_acronyms.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Menkes Kinky Hair Syndrome",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "serum sickness",
      "preferred_label": "serum sickness",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0043789",
        "orpha": null,
        "umls": "UMLS:C0036830",
        "mesh": "MESH:D012713"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0043789",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:11390",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D012713",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C79718",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:72284000",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0036830",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:715261250",
          "display": null
        }
      ],
      "context": "e Serious hypersensitivity reaction with, eg, bronchospasm or other respiratory reaction requiring ventilator support, symptomatic hypotension, or serum sickness-like reaction manifesting within 14 days after administration of the study intervention",
      "page": 30,
      "mention_count": 1,
      "pages_mentioned": [
        30
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "bronchospasm",
      "preferred_label": "bronchospasm",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "pulmonology",
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0001358",
        "orpha": null,
        "umls": "UMLS:C0006261",
        "mesh": "MESH:D001982"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0001358",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:1176",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:1002018",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:519.19",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:14233",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D001982",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C34439",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:41427001",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0006261",
          "display": null
        }
      ],
      "context": "e Serious hypersensitivity reaction with, eg, bronchospasm or other respiratory reaction requiring ventilator support, symptomatic hypotension, or serum sickness-like reaction manifesting within 14 days after administration of the study intervention",
      "page": 30,
      "mention_count": 1,
      "pages_mentioned": [
        30
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "rare disease",
      "preferred_label": "rare disease",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "rare_disease",
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0021200",
        "orpha": null,
        "umls": null,
        "mesh": "MESH:D035583"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0021200",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D035583",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C4873",
          "display": null
        }
      ],
      "context": "recruitment in regions with higher adolescent oMG prevalence; Collaborate with pediatric neurology networks and advocacy groups). Risk 5: Mitigate-Following the CDRC discussion the study will now be recruiting only adults -PCS is revised to reflect this change (note added on Sept 17, 2025) Leverage rare disease registries and referral centers. Provide travel support to reduce logistical barriers. Risk 6: Mitigate-Following the CDRC discussion the study will now be recruiting only adults -PCS is revised to reflect this change (note added on Sept 17, 2025) [Mitigations prior to CDRC meeting: Offer flexible",
      "page": 41,
      "mention_count": 1,
      "pages_mentioned": [
        41
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Rare Diseases",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "hepatitis B",
      "preferred_label": "Hepatitis B",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "gastroenterology",
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0005344",
        "orpha": null,
        "umls": "UMLS:C0019163",
        "mesh": "MESH:D006509"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0005344",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:2043",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0004197",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:070.30",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:6807",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D006509",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C3097",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:66071002",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0019163",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:1718385802",
          "display": null
        }
      ],
      "context": "e Evidence of hepatitis B or hepatitis C viral infection or presence of HBsAg or HBcAb with negative surface antibody (anti-HBs), or HCV infection (HCV antibody positive, expect for participants with document successful treatment). If locally available, SVR should be documented or established at Screening.",
      "page": 13,
      "mention_count": 1,
      "pages_mentioned": [
        13
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Hepatitis C",
        "Hepatitis B Chronic",
        "Hepatitis E"
      ],
      "pubtator_normalized_name": "Hepatitis B",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "hypotension",
      "preferred_label": "hypotension",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": "ICD10CM:I95",
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0005468",
        "orpha": null,
        "umls": "UMLS:C0020649",
        "mesh": "MESH:D007022"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0005468",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0005251",
          "display": null
        },
        {
          "system": "HP",
          "code": "HP:0002615",
          "display": null
        },
        {
          "system": "ICD-10-CM",
          "code": "ICD10CM:I95",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:458.9",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:5715",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D007022",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:45007003",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0020649",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:1663360295",
          "display": null
        }
      ],
      "context": "e Serious hypersensitivity reaction with, eg, bronchospasm or other respiratory reaction requiring ventilator support, symptomatic hypotension, or serum sickness-like reaction manifesting within 14 days after administration of the study intervention",
      "page": 30,
      "mention_count": 1,
      "pages_mentioned": [
        30
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "anaphylaxis",
      "preferred_label": "anaphylaxis",
      "abbreviation": null,
      "confidence": 0.85,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0100053",
        "orpha": null,
        "umls": "UMLS:C4316895",
        "mesh": "MESH:D000707"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0100053",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:1373755",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D000707",
          "display": null
        },
        {
          "system": "MedDRA",
          "code": "MedDRA:10002198",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C107101",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:39579001",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C4316895",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:1868068711",
          "display": null
        }
      ],
      "context": "(Accept/Mitigate) Discuss at rDRC (Yes/No) Safety RISK 1: Vaccination against Risk 1: Mitigate No Meningococcal infection - Ensuring vaccinations are administered as per local guidelines RISK 2: Delayed reporting of SAEs and pregnancies. RISK 3: Missing ADA/PK samples during immune-mediated events (anaphylaxis, hypersensitivity). Medical monitoring activities; Sites will be trained on the importance of vaccinations, the serotypes required to be covered before inclusion, and direct to local guidelines; Discussion from meetings: The meningococcal infection risk is inherent across all complement inhibition",
      "page": 44,
      "mention_count": 1,
      "pages_mentioned": [
        44
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "malignancy",
      "preferred_label": "malignancy",
      "abbreviation": null,
      "confidence": 0.85,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0004992",
        "orpha": null,
        "umls": "UMLS:C0006826",
        "mesh": "D009369"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0004992",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:162",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:199.1",
          "display": null
        },
        {
          "system": "ICDO",
          "code": "ICDO:8000/3",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:14297",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C9305",
          "display": null
        },
        {
          "system": "ONCOTREE",
          "code": "ONCOTREE:MT",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:363346000",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0006826",
          "display": null
        },
        {
          "system": "birnlex",
          "code": "birnlex:406",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D009369",
          "display": "Neoplasms"
        }
      ],
      "context": "e History of malignancy within 5 years of screening except",
      "page": 11,
      "mention_count": 1,
      "pages_mentioned": [
        11
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Hematologic Neoplasms",
        "Leukemia Lymphocytic Chronic B-Cell",
        "Neoplasms Second Primary"
      ],
      "pubtator_normalized_name": "Neoplasms",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "condition",
      "preferred_label": "condition",
      "abbreviation": null,
      "confidence": 0.65,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0000001",
        "orpha": "Orphanet:377788",
        "umls": "UMLS:C0012634",
        "mesh": "MESH:D004194"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0000001",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:4",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:799.9",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:4347",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D004194",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C2991",
          "display": null
        },
        {
          "system": "OGMS",
          "code": "OGMS:0000031",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:377788",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:64572001",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0012634",
          "display": null
        }
      ],
      "context": "hani, 2023; Kerty, 2014), resulting in chronic and fluctuating diplopia and ptosis. Effective management of oMG requires continuous control of the mechanisms responsible for the disease’s pathophysiology. Achievement and maintenance of a status at which clinical signs and symptoms of the underlying condition are absent or minimally present is widely accepted as the treatment goal for various chronic disabling immuno-mediated diseases (eg, bronchial asthma, inflammatory bowel disease, multiple sclerosis, and rheumatoid arthritis).",
      "page": 2,
      "mention_count": 2,
      "pages_mentioned": [
        2
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Chronic Disease",
        "Precancerous Conditions",
        "Muscular Diseases"
      ],
      "pubtator_normalized_name": "Neurodegenerative Diseases",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "infection",
      "preferred_label": "infection",
      "abbreviation": null,
      "confidence": 0.85,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": "ICD10CM:A00-B99",
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0005550",
        "orpha": null,
        "umls": "UMLS:C0009450",
        "mesh": "MESH:D003141"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0005550",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:0050117",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0005741",
          "display": null
        },
        {
          "system": "ICD-10-CM",
          "code": "ICD10CM:A00-B99",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:136.9",
          "display": null
        },
        {
          "system": "IDO",
          "code": "IDO:0000436",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:1057",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D003141",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C26726",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:40733004",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0009450",
          "display": null
        }
      ],
      "context": "e History of N meningitidis infection",
      "page": 11,
      "mention_count": 1,
      "pages_mentioned": [
        11
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "COVID-19",
        "HIV Infections",
        "Virus Diseases"
      ],
      "pubtator_normalized_name": "Infections",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "amblyopia",
      "preferred_label": "amblyopia",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0001020",
        "orpha": null,
        "umls": "UMLS:C0002418",
        "mesh": "MESH:D000550"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0001020",
          "display": null
        },
        {
          "system": "CSP",
          "code": "CSP:1114-9655",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:10376",
          "display": null
        },
        {
          "system": "HP",
          "code": "HP:0000646",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:368.00",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:8009",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D000550",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C118764",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:387742006",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0002418",
          "display": null
        }
      ],
      "context": "e History of amblyopia, cross eyes etc. or any other ocular condition which might interfere with accurate study assessments",
      "page": 12,
      "mention_count": 1,
      "pages_mentioned": [
        12
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Amblyopia",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "hepatitis",
      "preferred_label": "Hepatitis",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "gastroenterology",
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0002251",
        "orpha": null,
        "umls": "UMLS:C0019158",
        "mesh": "MESH:D006505"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0002251",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:2237",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:571.41",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:5515",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D006505",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C3095",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:197268000",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0019158",
          "display": null
        }
      ],
      "context": "e Evidence of hepatitis B or hepatitis C viral infection or presence of HBsAg or HBcAb with negative surface antibody (anti-HBs), or HCV infection (HCV antibody positive, expect for participants with document successful treatment). If locally available, SVR should be documented or established at Screening.",
      "page": 13,
      "mention_count": 1,
      "pages_mentioned": [
        13
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Hepatitis C Chronic",
        "Hepatitis C",
        "Hepatitis E"
      ],
      "pubtator_normalized_name": "Hepatitis B",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "acquired",
      "preferred_label": "acquired",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0021141",
        "orpha": "Orphanet:409941",
        "umls": null,
        "mesh": null
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0021141",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:409941",
          "display": null
        }
      ],
      "context": "Risk Response (Accept/Mitigate) Discuss at rDRC (Yes/No) Mitigations prior to CDRC meeting: Site planning and patient communication must be closely managed, especially for remote visits. Train participants on study intervention administration before self-administering at home. Certification will be acquired. Discussion 02092025: This is part of the PCS-Participants have to be trained and certified before self-administering at home. Discussion 04092025: Highlighted the risk of incorrect self-administration, even with training and certification of participants. Potential issues included incorrect needle",
      "page": 43,
      "mention_count": 1,
      "pages_mentioned": [
        43
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "Sterile",
      "preferred_label": "sterile",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0005047",
        "orpha": null,
        "umls": "UMLS:C0021359",
        "mesh": "MESH:D007246"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0005047",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:5223",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0000545",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:43876",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D007246",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C3836",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0021359",
          "display": null
        }
      ],
      "context": "Group Name Treatment 1 Treatment 2 Intervention Name ALXN1720-PFS-SD Placebo-PFS-SD Type Integral medicinal product: biological product and device Integral medicinal product: placebo formulation and device Dose Formulation Sterile liquid gefurulimab is formulated at pH 6.7 and each syringe contains 300 mg of gefurulimab in 20 mM L-histidine/histidine hydrochloride, 100 mM glycine, 200 mM sucrose, 0.08% (w/v) polysorbate 80 Device configuration/style/model: BD 2.25mL Neopak™ Prefilled Syringe with Ultrasafe Plus™ Passive Need",
      "page": 14,
      "mention_count": 1,
      "pages_mentioned": [
        14
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Pyogenic arthritis pyoderma gangrenosum and acne",
        "Deficiency of interleukin-1 receptor antagonist"
      ],
      "pubtator_normalized_name": "Brain Abscess",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "ptosis",
      "preferred_label": "ptosis",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0000728",
        "orpha": null,
        "umls": "UMLS:C0005745",
        "mesh": "MESH:D001763"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0000728",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:0060260",
          "display": null
        },
        {
          "system": "HP",
          "code": "HP:0000508",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:374.30",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:2287",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D001763",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C27298",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:11934000",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0005745",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:1361674069",
          "display": null
        }
      ],
      "context": "eptor loss or damage and reduced expression of complement regulatory proteins on ocular muscle fibers (Bril, 2024; Soltys, 2008). A proportion of oMG patients do not achieve adequate control with current SoC treatment (Behbehani, 2023; Kerty, 2014), resulting in chronic and fluctuating diplopia and ptosis. Effective management of oMG requires continuous control of the mechanisms responsible for the disease’s pathophysiology. Achievement and maintenance of a status at which clinical signs and symptoms of the underlying condition are absent or minimally present is widely accepted as the treatment goal",
      "page": 2,
      "mention_count": 2,
      "pages_mentioned": [
        2,
        12
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Horner Syndrome",
        "Carnevale syndrome",
        "Blepharoptosis"
      ],
      "pubtator_normalized_name": "Ptosis Hereditary Congenital 2",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "asthma",
      "preferred_label": "asthma",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "pulmonology",
      "codes": {
        "icd10": "ICD10CM:J45",
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0004979",
        "orpha": null,
        "umls": "UMLS:C0004096",
        "mesh": "MESH:D001249"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0004979",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:2841",
          "display": null
        },
        {
          "system": "HP",
          "code": "HP:0002099",
          "display": null
        },
        {
          "system": "ICD-10-CM",
          "code": "ICD10CM:J45",
          "display": null
        },
        {
          "system": "ICD10WHO",
          "code": "ICD10WHO:J45",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:493.9",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:2109",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D001249",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C28397",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:31387002",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0004096",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:1656445230",
          "display": null
        }
      ],
      "context": "isms responsible for the disease’s pathophysiology. Achievement and maintenance of a status at which clinical signs and symptoms of the underlying condition are absent or minimally present is widely accepted as the treatment goal for various chronic disabling immuno-mediated diseases (eg, bronchial asthma, inflammatory bowel disease, multiple sclerosis, and rheumatoid arthritis).",
      "page": 2,
      "mention_count": 1,
      "pages_mentioned": [
        2
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Status Asthmaticus",
        "Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome",
        "Ige Responsiveness Atopic"
      ],
      "pubtator_normalized_name": "Asthma",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "injury",
      "preferred_label": "injury",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0021178",
        "orpha": null,
        "umls": null,
        "mesh": "MESH:D014947"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0021178",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0000546",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D014947",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C3671",
          "display": null
        }
      ],
      "context": "nd includes symptomatic treatment with AChE inhibitors, disease-modifying treatment with steroids, steroid-sparing immunosuppressants. None of the standard chronic or maintenance treatment options specifically address the autoimmune defect in MG or the underlying pathophysiology or mechanism of NMJ injury due to anti-AChR antibody-AChR interactions, complement activation, and the resultant NMJ destruction. Gefurulimab was developed for the treatment of gMG with these needs in mind and is now being evaluated for oMG.",
      "page": 3,
      "mention_count": 1,
      "pages_mentioned": [
        3
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Chemical and Drug Induced Liver Injury",
        "Smoke Inhalation Injury",
        "Acute Kidney Injury"
      ],
      "pubtator_normalized_name": "Wounds and Injuries",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "MACs",
      "preferred_label": "MACS",
      "abbreviation": null,
      "confidence": 0.6,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0100004",
        "orpha": null,
        "umls": "UMLS:C5200989",
        "mesh": "MESH:D000090267"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0100004",
          "display": null
        },
        {
          "system": "GARD",
          "code": "GARD:12981",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:1698540",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D000090267",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C5200989",
          "display": null
        }
      ],
      "context": "Anti-AChR autoantibodies are immunoglobulins of the G1 and G3 subtypes which attract complement component Clq. Deposition of Clq triggers the classical complement pathway leading to the cleavage of C5 into C5a and C5b. C5b initiates the assembly of the MACs and destruction of the motor end plate (Dalakas, 2020; Gavriilaki, 2020), reducing the efficiency and reliability of neuromuscular signalling.",
      "page": 2,
      "mention_count": 1,
      "pages_mentioned": [
        2
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Macrocephaly Alopecia Cutis Laxa and Scoliosis",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "PROs",
      "preferred_label": "PROS",
      "abbreviation": null,
      "confidence": 0.6,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0035162",
        "orpha": "Orphanet:530313",
        "umls": null,
        "mesh": null
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0035162",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:530313",
          "display": null
        }
      ],
      "context": "92025: Diplopia or Ptosis will not compromise consent comprehension or PRO completion because we are able to consent people who are severely visually compromised. Consents are just read out to them by someone else and then we ask for comprehension. Consent would be read out to people who need help. PROs could be completed by asking them over the phone for remote visits. If they have ptosis, it's painful when you are lifting one eyelid. In case anybody has severe ptosis, we can always ask the questions and then the administrator can note down the responses. Risk 3: Diagnostic Misclassification: Ris",
      "page": 40,
      "mention_count": 1,
      "pages_mentioned": [
        40
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "ADA",
      "preferred_label": "ADA",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0007064",
        "orpha": "Orphanet:277",
        "umls": "UMLS:C0392607",
        "mesh": "MESH:C531816"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0007064",
          "display": null
        },
        {
          "system": "CSP",
          "code": "CSP:1560-6660",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:5810",
          "display": null
        },
        {
          "system": "GARD",
          "code": "GARD:5748",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:277.2",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:95935",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:C531816",
          "display": null
        },
        {
          "system": "MedDRA",
          "code": "MedDRA:10066367",
          "display": null
        },
        {
          "system": "NANDO",
          "code": "NANDO:2200696",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C3962",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "OMIM:102700",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:277",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:44940001",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0392607",
          "display": null
        }
      ],
      "context": "characterize the PK/PD of gefurulimab in participants with OMG e Serum gefurulimab concentrations e Absolute values, change from Baseline, and percent change from Baseline in serum free and total C5 concentrations Immunogenicity: To assess the immunogenicity to gefurulimab in participants with oMG ADA incidence, response categories, and titer over time for the duration of the study Safety: To assess the safety and tolerability of gefurulimab compared to placebo and the long-term safety and tolerability of gefurulimab in participants with OMG e Incidence and severity of AEs and SAEs e Clinically",
      "page": 5,
      "mention_count": 1,
      "pages_mentioned": [
        5
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Syncope",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "EOS",
      "preferred_label": "EOS",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0008523",
        "orpha": "Orphanet:90341",
        "umls": "UMLS:C5201146",
        "mesh": "MESH:C538157"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0008523",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:0050678",
          "display": null
        },
        {
          "system": "GARD",
          "code": "GARD:304",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:714.89",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:1684759",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:C538157",
          "display": null
        },
        {
          "system": "MedDRA",
          "code": "MedDRA:10071755",
          "display": null
        },
        {
          "system": "NANDO",
          "code": "NANDO:2200434",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C116794",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "OMIM:609464",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:90341",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:699861000",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C5201146",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:382488319",
          "display": null
        }
      ],
      "context": "If a participant discontinues treatment or withdraws from the study early or completes the study prior to the end of the OLE Period, the participant will be encouraged to return for an ET/EOS Visit as soon as possible.",
      "page": 7,
      "mention_count": 1,
      "pages_mentioned": [
        7
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Eosinophilic Esophagitis",
        "Eosinophilic Granuloma",
        "Eosinophilic enteropathy"
      ],
      "pubtator_normalized_name": "Eosinophilia",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "CSP",
      "preferred_label": "CSP",
      "abbreviation": null,
      "confidence": 0.6,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0005078",
        "orpha": null,
        "umls": "UMLS:C0010701",
        "mesh": "MESH:D003557"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0005078",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0000653",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:1209",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D003557",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C2977",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0010701",
          "display": null
        }
      ],
      "context": "Inclusion and exclusion criteria are provided below. Note these are not inclusive of entire list from CSP template, which will be included at time of protocol development",
      "page": 9,
      "mention_count": 1,
      "pages_mentioned": [
        9
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "CIS",
      "preferred_label": "CIS",
      "abbreviation": null,
      "confidence": 0.6,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0004647",
        "orpha": null,
        "umls": "UMLS:C0007099",
        "mesh": "MESH:D002278"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0004647",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:8719",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:234.9",
          "display": null
        },
        {
          "system": "ICDO",
          "code": "ICDO:8010/2",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:763",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D002278",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C2917",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:109355002",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0007099",
          "display": null
        }
      ],
      "context": "— treated Cervical CIS without recurrence",
      "page": 11,
      "mention_count": 1,
      "pages_mentioned": [
        11
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "DMC",
      "preferred_label": "DMC",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0009130",
        "orpha": "Orphanet:239",
        "umls": "UMLS:C0265286",
        "mesh": null
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0009130",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:0111167",
          "display": null
        },
        {
          "system": "GARD",
          "code": "GARD:6295",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:120527",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C124844",
          "display": null
        },
        {
          "system": "NORD",
          "code": "NORD:1068",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "OMIM:223800",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:239",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:82699004",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0265286",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:21266164",
          "display": null
        }
      ],
      "context": "To manage the uncertainty associated with the assumed treatment effect for the primary endpoint, an interim analysis for sample size re-estimation will be performed after approximately 56 participants have completed Week 12 of the RCT Period. The analysis will be reviewed by an independent DMC. The sample size may be increased to a maximum of 186 participants if the conditional power based on the estimated treatment effect in the primary endpoint falls within",
      "page": 15,
      "mention_count": 1,
      "pages_mentioned": [
        15
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "PPS",
      "preferred_label": "PPS",
      "abbreviation": null,
      "confidence": 0.6,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0017435",
        "orpha": "Orphanet:294963",
        "umls": "UMLS:C0265259",
        "mesh": "MESH:C562509"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0017435",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:0060055",
          "display": null
        },
        {
          "system": "GARD",
          "code": "GARD:21189",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:756.89",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:78543",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:C562509",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C118786",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:294963",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:66783006",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0265259",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:543218573",
          "display": null
        }
      ],
      "context": "The Full Analysis Set (FAS) will be the primary population used for the analysis of all efficacy endpoints for the RCT Period. Supplemental per protocol analyses for primary and secondary efficacy endpoints will be performed based on the Per Protocol Set (PPS) in the same manner as done for the FAS. Safety analyses will be performed on the Safety Set (SS).",
      "page": 16,
      "mention_count": 1,
      "pages_mentioned": [
        16
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "SAS",
      "preferred_label": "SAS",
      "abbreviation": null,
      "confidence": 0.6,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0100147",
        "orpha": "Orphanet:576278",
        "umls": null,
        "mesh": null
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0100147",
          "display": null
        },
        {
          "system": "GARD",
          "code": "GARD:22326",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:576278",
          "display": null
        }
      ],
      "context": "Analyses will be performed using the SAS software Version 9.4 or higher.",
      "page": 16,
      "mention_count": 1,
      "pages_mentioned": [
        16
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "Lan",
      "preferred_label": "LAN",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0020619",
        "orpha": null,
        "umls": null,
        "mesh": "D007806"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0020619",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "OMIM:111600",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D007806",
          "display": "Language Disorders"
        }
      ],
      "context": "Hierarchical testing procedure will be followed for the testing of primary and key secondary endpoints. The overall type I error of the study for this interim and the final analysis is controlled at 1-sided 0.025 using the Lan & DeMets a-spending approximation to the O’Brien & Fleming boundaries for primary endpoint and Lan & DeMets a-spending approximation to the Pocock boundaries for key secondary endpoints.",
      "page": 18,
      "mention_count": 1,
      "pages_mentioned": [
        18
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Language Development Disorders",
        "Apraxias"
      ],
      "pubtator_normalized_name": "Language Disorders",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "ENS",
      "preferred_label": "ENS",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_1060148",
        "orpha": null,
        "umls": "UMLS:C3888849",
        "mesh": null
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_1060148",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:1876481",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C3888849",
          "display": null
        }
      ],
      "context": "Kerty E, Elsais A, Argov Z, Evoli A, Gilhus NE. EFNS/ENS Guidelines for the treatment of ocular myasthenia. Eur J Neurol. 2014;21(5):687-693.",
      "page": 38,
      "mention_count": 1,
      "pages_mentioned": [
        38
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "PCS",
      "preferred_label": "PCS",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0008304",
        "orpha": null,
        "umls": "UMLS:C1864389",
        "mesh": null
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0008304",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:400517",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "OMIM:176430",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C1864389",
          "display": null
        }
      ],
      "context": "Risk Category Risk Description Risk Response (Accept/Mitigate) Discuss at rDRC (Yes/No) Participant population Risk 1: Adolescent Challenges: Risk 1: Mitigate — Following the CDRC discussion the study will | No Differential PK/PD, adherence issues, | now be recruiting only adults -PCS is revised to reflect this and consent complexities in patients change (note added on Sept 17, 2025) aged 12-17. (Mitigations prior to the CRDC meeting: Implement frequent monitoring for adherence via patient diaries and reminders; Develop age-specific consent/assent training and materials to ensur",
      "page": 40,
      "mention_count": 1,
      "pages_mentioned": [
        40
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "MRD",
      "preferred_label": "MRD",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0019982",
        "orpha": "Orphanet:97364",
        "umls": "UMLS:C1840451",
        "mesh": null
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0019982",
          "display": null
        },
        {
          "system": "GARD",
          "code": "GARD:9517",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:333563",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:97364",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:717749002",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C1840451",
          "display": null
        }
      ],
      "context": "e data is transferred by the CRO before DBL. We’ve noticed in other programs that many samples were with status ‘pending analysis’. Data should be transferred in the correct agreed format, this should be checked thoroughly during mock data transfer Titer values should be appropriately reported with MRD factored in. Risk 2: Mitigate-Following the CDRC discussion the study will now be recruiting only adults -PCS is revised to reflect this change (note added on Sept 17, 2025) Simplify visit schedules and procedures in the clinical study protocol (CSP) where feasible. Offer remote visit options or tr",
      "page": 48,
      "mention_count": 1,
      "pages_mentioned": [
        48
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    }
  ]
}